JP2014097964A5 - - Google Patents

Download PDF

Info

Publication number
JP2014097964A5
JP2014097964A5 JP2012251831A JP2012251831A JP2014097964A5 JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5 JP 2012251831 A JP2012251831 A JP 2012251831A JP 2012251831 A JP2012251831 A JP 2012251831A JP 2014097964 A5 JP2014097964 A5 JP 2014097964A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
deuterium
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012251831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014097964A (ja
JP6146990B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012251831A priority Critical patent/JP6146990B2/ja
Priority claimed from JP2012251831A external-priority patent/JP6146990B2/ja
Publication of JP2014097964A publication Critical patent/JP2014097964A/ja
Publication of JP2014097964A5 publication Critical patent/JP2014097964A5/ja
Application granted granted Critical
Publication of JP6146990B2 publication Critical patent/JP6146990B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012251831A 2012-11-16 2012-11-16 重水素化されたcftr増強物質 Active JP6146990B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012251831A JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017022718A Division JP2017105824A (ja) 2017-02-10 2017-02-10 重水素化されたcftr増強物質

Publications (3)

Publication Number Publication Date
JP2014097964A JP2014097964A (ja) 2014-05-29
JP2014097964A5 true JP2014097964A5 (enExample) 2016-01-07
JP6146990B2 JP6146990B2 (ja) 2017-06-14

Family

ID=50940312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012251831A Active JP6146990B2 (ja) 2012-11-16 2012-11-16 重水素化されたcftr増強物質

Country Status (1)

Country Link
JP (1) JP6146990B2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
CA3294570A1 (en) * 2015-06-30 2026-03-02 Eiger Group International, Inc. Use of r-chloroquine or metabolites, r-rhydroxychloroquine or metabolites, or deuterated analogs of r-chloroquine or rhydroxychloroquine, in treatment of liver inflammation
HUP1600271A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
HUP1600270A2 (hu) 2016-04-25 2017-10-30 Druggability Tech Ip Holdco Ltd Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
US10206915B2 (en) 2016-04-25 2019-02-19 Druggability Technologies Ip Holdco Limited Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en) 2016-04-25 2019-08-20 Druggability Technologies Ip Holdco Limited Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
JP6802899B2 (ja) * 2016-07-25 2020-12-23 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. 置換ボロン酸化合物、該化合物を含む医薬組成物およびその使用
JP2017105824A (ja) * 2017-02-10 2017-06-15 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたcftr増強物質
WO2019109021A1 (en) * 2017-12-01 2019-06-06 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
JP6654223B2 (ja) * 2018-08-13 2020-02-26 バーテックス ファーマシューティカルズ (ヨーロッパ) リミテッド 重水素化されたcftr増強物質
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) * 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
EA007590B1 (ru) * 2002-04-08 2006-12-29 Пфайзер Инк. Производные тропана в качестве модуляторов ccr5
AU2003278602C1 (en) * 2002-06-20 2010-08-12 Pronova Biopharma Norge As Sulfur-containing phospholipid derivatives
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ME03652B (me) * 2011-05-18 2020-07-20 Vertex Pharmaceuticals Europe Ltd Deuterisani derivati ivakaftora

Similar Documents

Publication Publication Date Title
JP2014515351A5 (enExample)
JP2015528020A5 (enExample)
JP2018534348A5 (enExample)
JP2013537203A5 (enExample)
JP2015145426A5 (enExample)
JP2013032389A5 (enExample)
JP2014500861A5 (enExample)
JP2015512432A5 (enExample)
JP2011037841A5 (enExample)
JP2013542261A5 (enExample)
JP2016500111A5 (enExample)
JP2013509429A5 (enExample)
JP2016529306A5 (enExample)
JP2017537066A5 (enExample)
JP2010001302A5 (enExample)
RU2018114447A (ru) Введение дейтерированных усилителей cftr
JP2012072150A5 (enExample)
JP2014515013A5 (enExample)
JP2015537020A5 (enExample)
JP2013510120A5 (enExample)
JP2013539448A5 (enExample)
JP2016540749A5 (enExample)
JP2012519182A5 (enExample)
JP2012532883A5 (enExample)
JP2014503593A5 (enExample)